Skyline Ventures India Ltd vs Welcure Drugs Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Skyline Ventures India Ltd is ₹ 22 as of 06 Jul 15:30 . The P/E Ratio of Skyline Ventures India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Welcure Drugs & Pharmaceuticals Ltd changed from 37.6 on March 2021 to 47.8 on March 2025 . This represents a CAGR of 4.92% over 5 years The Market Cap of Skyline Ventures India Ltd changed from ₹ 11.31 crore on March 2025 to ₹ 11.31 crore on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Welcure Drugs & Pharmaceuticals Ltd changed from ₹ 2.54 crore on March 2021 to ₹ 102.13 crore on March 2025 . This represents a CAGR of 109.35% over 5 years The revenue of Skyline Ventures India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Welcure Drugs & Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 1.46 crore. This represent the decline of -100% The ebitda of Skyline Ventures India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Welcure Drugs & Pharmaceuticals Ltd for the Mar '26 is ₹ -49.86 crore as compare to the Dec '25 ebitda of ₹ 1.43 crore. This represent the decline of -3586% The net profit of Skyline Ventures India Ltd changed from ₹ -0.04 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Welcure Drugs & Pharmaceuticals Ltd changed from ₹ -0.34 crore to ₹ -49.86 crore over 8 quarters. This represents a CAGR of 1110.98% The Dividend Payout of Skyline Ventures India Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Welcure Drugs & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Skyline Ventures India Ltd

Skyline Ventures India Limited was initially incorporated as Vishwakarma Securities Limited on November 17, 1988.
Name of the Company was changed from Vishwakarma Securities Limited to Paramatma Enterprises Limited on December 27, 2005 and further was renamed as Skyline Ventures India Limited on November 11, 2010.
The Company started operations as an investment Company in Andhra Pradesh.
The Company diversified the business operations in 2005 into the infrastructure, power and other sectors and is presently engaged into the business of Construction and Trading. The Company has a well diversified business portfolio spread across ten business verticals viz., Buildings & Housing, Roads, Water & Environment, Electrical, Irrigation, Metals, Power, International, Mining and Railways.
It executed complex engineering projects across the country.

About Welcure Drugs & Pharmaceuticals Ltd

Incorporated on 4th June, 1992, Welcure Drugs And Pharmaceuticals Limited(WDPL) was promoted by D C Jain, Sanjeev Jain and Sandeep Jain.
The promoters have interests in other companies such as Paam Pharmaceuticals, Pioneer Products, Alirox Abrasives, A K Laboratories, etc. WDPL had come out with a Rs 4-cr public issue in Aug.'94 to part-finance the Rs 12 Crore project to manufacture bulk drugs in Rajasthan and finance investments in a subsidiary, A K Laboratories (AKL).
The company has also submitted the letter of offer for a Rs 7.09-cr rights issue of equity shares in Jan.'96 to finance its expansion programmes. Products of WDPL include bulk drugs such as ampicillin and trimethoprim, drugs intermediates and pharmaceutical formulations.
It has decided to add amoxycillin and cloxacillin to its range with provision to manufacture ibuprofen.

FAQs for the comparison of Skyline Ventures India Ltd and Welcure Drugs & Pharmaceuticals Ltd

Which company has a larger market capitalization, Skyline Ventures India Ltd or Welcure Drugs & Pharmaceuticals Ltd?

Market cap of Skyline Ventures India Ltd is 7 Cr while Market cap of Welcure Drugs & Pharmaceuticals Ltd is 22 Cr

What are the key factors driving the stock performance of Skyline Ventures India Ltd and Welcure Drugs & Pharmaceuticals Ltd?

The stock performance of Skyline Ventures India Ltd and Welcure Drugs & Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Skyline Ventures India Ltd and Welcure Drugs & Pharmaceuticals Ltd?

As of October 25, 2026, the Skyline Ventures India Ltd stock price is INR ₹19.0. On the other hand, Welcure Drugs & Pharmaceuticals Ltd stock price is INR ₹0.18.

How do dividend payouts of Skyline Ventures India Ltd and Welcure Drugs & Pharmaceuticals Ltd compare?

To compare the dividend payouts of Skyline Ventures India Ltd and Welcure Drugs & Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.